Seattle Genetics Kills $2B Deal with Immunomedics

May 05, 2017

The Seattle Times

Seattle Genetics withdrew its potential $2 billion deal after a shareholder revolt at New Jersey-based Immunomedics removed its top executives, according to The Seattle Times.

In February, Biotech Seattle Genetics agreed to pay $250 million upfront to license a potential solid-tumor drug developed by Immunomedics. Future milestone and royalty payments could have increased the total to $2 billion. But the companies agreed to terminate their licensing agreement over the drug, known as IMMU-132.

Immunomedics said its founder and his wife, the CEO, have stepped down, and the company has raised $125 million to fund the drug’s development on its own, the story said.

Read the full article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments